Dyne Therapeutics, Inc. (DYN)
NASDAQ
Closed
Sep 21, 2026
Day's Range
16.7552 wk Range
11.92Overview - DYN - Dyne Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
2.53B
P/E (Trailing)
‪-4.93‬
P/E (Forward)
‪-5.13‬
PEG Ratio
‪-0.43‬
Price / Book
‪4.03‬
EV / EBITDA
‪-4.73‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-38.95%‬
Return on Equity
‪-81.56%‬
Ownership
Shares Outstanding
165.67M
Float
186.23M
Short % of Shares Outstanding
‪14.24%‬
Held by Insiders
‪0.23%‬
Held by Institutions
‪103.68%‬
Price stats
Beta
‪1.07‬
50-Day Avg
‪23.98‬
200-Day Avg
‪19.80‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
17 analysts
Average price target
‪$ 39.40‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - DYN - Dyne Therapeutics, Inc.
Peers - DYN - Dyne Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- DYNNASDAQDyne Therapeutics, Inc.3.19BMarket Cap+21.45%52-week change-4.93P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE61.58BMarket Cap+25.27%52-week change37.92P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.32.05BMarket Cap-91.57%52-week change41.68P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE24.13BMarket Cap-2.77%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.57BMarket Cap+17.02%52-week change18.34P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.02BMarket Cap+22.62%52-week change-17.62P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.37BMarket Cap+15.64%52-week change172.81P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - DYN - Dyne Therapeutics, Inc.
About
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for genetically driven neuromuscular diseases. Dyne Therapeutics advances a pipeline of investigational medicines designed to deliver treatment directly to muscle tissue and, in some programs, the central nervous…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
